Scoop: Boehringer quietly shutters a PhII for one of its top drugs — now under review
Boehringer Ingelheim has quietly shut down a small Phase II study for one of its lead drugs.
The private pharma player confirmed to Endpoints News …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
